N
EWTX icon

Nuveen’s Edgewise Therapeutics EWTX Stock Holding History

Nuveen’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.6M Buy
335,783
+166,317
+98% +$4.8M ﹤0.01% 1514
2025
Q4 		$4.21M Sell
169,466
-3,241
-2% -$65.1K ﹤0.01% 1988
2025
Q3 		$2.8M Sell
172,707
-144,466
-46% -$2.05M ﹤0.01% 2155
2025
Q2 		$4.16M Buy
317,173
+114,593
+57% +$1.65M ﹤0.01% 1967
2025
Q1 		$4.46M Sell
202,580
-226,278
-53% -$5.94M ﹤0.01% 1980
2024
Q4 		$11.5M Buy
428,858
+158,452
+59% +$5.05M ﹤0.01% 1528
2024
Q3 		$7.22M Buy
270,406
+27,308
+11% +$543K ﹤0.01% 1803
2024
Q2 		$4.38M Sell
243,098
-94,906
-28% -$1.66M ﹤0.01% 2023
2024
Q1 		$6.17M Buy
338,004
+184,712
+120% +$2.94M ﹤0.01% 1866
2023
Q4 		$1.68M Buy
153,292
+806
+0.5% +$5.66K ﹤0.01% 2496
2023
Q3 		$874K Sell
152,486
-1,016
-0.7% -$6.91K ﹤0.01% 2628
2023
Q2 		$1.19M Buy
153,502
+55,678
+57% +$470K ﹤0.01% 2588
2023
Q1 		$653K Sell
97,824
-8,878
-8% -$82.3K ﹤0.01% 2741
2022
Q4 		$954K Sell
106,702
-4,907
-4% -$46K ﹤0.01% 2699
2022
Q3 		$1.1M Sell
111,609
-2,728
-2% -$27.6K ﹤0.01% 2713
2022
Q2 		$910K Buy
114,337
+4,222
+4% +$31.9K ﹤0.01% 2827
2022
Q1 		$1.15M Buy
110,115
+16,765
+18% +$216K ﹤0.01% 2766
2021
Q4 		$1.8M Buy
93,350
+64,387
+222% +$1.16M ﹤0.01% 2616
2021
Q3 		$501K Sell
28,963
-17,877
-38% -$323K ﹤0.01% 3167
2021
Q2 		$999K Buy
+46,840
New +$1.28M ﹤0.01% 3005

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Nuveen's EWTX Position: Q1 2026 in Review

Nuveen increased its Edgewise Therapeutics (EWTX) stake by 98% in Q1 2026, buying an estimated $4.8M and bringing the position to 335,783 shares worth $10.6M. The position accounts for ﹤0.01% of the portfolio, ranked #1514.

Nuveen first reported a position in EWTX in Q2 2021 and has held it in 20 quarters since. The position peaked at $11.5M in Q4 2024. 214 funds tracked by Wall St. Rank hold EWTX as of Q1 2026.

  • Nuveen held 335,783 shares of Edgewise Therapeutics worth $10.6M as of Q1 2026.
  • Nuveen bought 166,317 Edgewise Therapeutics shares in Q1 2026, an estimated $4.8M.
  • Edgewise Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q1 2026, its #1514 holding.
  • Nuveen first reported a position in Edgewise Therapeutics in Q2 2021 and has held it in 20 quarters since.
  • Nuveen's Edgewise Therapeutics position peaked at $11.5M in Q4 2024.
  • 214 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q1 2026.

Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.